-
EP1368031
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1368031
| EP1368031 - METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 13.12.2013 Database last updated on 14.03.2026 | Most recent event Tooltip | 13.12.2013 | Withdrawal of application | published on 15.01.2014 [2014/03] | Applicant(s) | For all designated states Aventis Pharmaceuticals Inc. 300 Somerset Corporate Boulevard Bridgewater, New Jersey 08807 / US | [N/P] |
| Former [2006/44] | For all designated states Aventis Pharmaceuticals, Inc. 300 Somerset Corporate Boulevard Bridgewater, New Jersey 08807 / US | ||
| Former [2003/50] | For all designated states Aventis Pharmaceuticals, Inc. 300 Somerset Corporate Boulevard Bridgwater, New Jersey 08807-2854 / US | Inventor(s) | 01 /
SMITH, Craig, P. 531 Brookside Lane Hillsborough, NJ 08844 / US | 02 /
RATHBONE, Michel, P. 15 Ricardo Court Hamilton, Ontario L8N 3Z5 / CA | 03 /
PETTY, Margaret 64 Bradley Lane Bridgewater, NJ 08807 / US | 04 /
RAMPE, David 36 Prospect Street Bernardsville, NJ 07924 / US | [2003/50] | Representative(s) | Wein, Elmar Michael Sanofi-Aventis Deutschland GmbH Global Intellectual Property Department Industriepark Höchst Gebäude K 703 65926 Frankfurt am Main / DE | [N/P] |
| Former [2003/50] | Wein, Elmar Michael, Dr. Aventis Pharma Deutschland GmbH, Patent- und Lizenzabteilung, K 801, Industriepark Höchst 65926 Frankfurt am Main / DE | Application number, filing date | 02714974.9 | 14.02.2002 | [2003/50] | WO2002US05501 | Priority number, date | US20010268846P | 15.02.2001 Original published format: US 268846 P | GB20010019435 | 09.08.2001 Original published format: GB 0119435 | [2003/50] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO02064126 | Date: | 22.08.2002 | Language: | EN | [2002/34] | Type: | A2 Application without search report | No.: | EP1368031 | Date: | 10.12.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.08.2002 takes the place of the publication of the European patent application. | [2003/50] | Search report(s) | International search report - published on: | EP | 20.02.2003 | Classification | IPC: | A61K31/4439 | [2003/50] | CPC: |
A61K31/4439 (EP,KR,US);
A61P13/00 (EP);
A61P13/02 (EP);
A61P13/10 (EP);
A61P17/02 (EP);
A61P19/00 (EP);
A61P19/02 (EP);
A61P19/08 (EP);
A61P25/00 (EP);
A61P25/02 (EP);
A61P25/04 (EP);
A61P25/28 (EP);
A61P27/02 (EP);
A61P29/00 (EP);
A61P3/00 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P43/00 (EP);
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/50] | Extension states | AL | 15.09.2003 | LT | 15.09.2003 | LV | 15.09.2003 | MK | 15.09.2003 | RO | 15.09.2003 | SI | 15.09.2003 | Title | German: | VERFAHREN ZUR BEHANDLUNG VON DEMYELINISIERENDEN ERKRANKUNGEN | [2003/50] | English: | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | [2003/50] | French: | METHODE DESTINEE AU TRAITEMENT DE PATHOLOGIES OU DE TROUBLES LIES A LA DEMYELINISATION | [2003/50] | Entry into regional phase | 15.09.2003 | National basic fee paid | 15.09.2003 | Designation fee(s) paid | 15.09.2003 | Examination fee paid | Examination procedure | 13.09.2002 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 15.09.2003 | Examination requested [2003/50] | 20.06.2007 | Despatch of a communication from the examining division (Time limit: M06) | 27.12.2007 | Reply to a communication from the examining division | 24.07.2013 | Despatch of a communication from the examining division (Time limit: M06) | 10.12.2013 | Application withdrawn by applicant [2014/03] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.06.2007 | Fees paid | Renewal fee | 01.03.2004 | Renewal fee patent year 03 | 28.02.2005 | Renewal fee patent year 04 | 28.02.2006 | Renewal fee patent year 05 | 28.02.2007 | Renewal fee patent year 06 | 29.02.2008 | Renewal fee patent year 07 | 02.03.2009 | Renewal fee patent year 08 | 01.03.2010 | Renewal fee patent year 09 | 15.02.2011 | Renewal fee patent year 10 | 15.02.2012 | Renewal fee patent year 11 | 28.02.2013 | Renewal fee patent year 12 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] MYSIW W.J. ET AL: "Medications to enhance cognitive functioning.", PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, (1997) 8/4 (781-800)., XP001096032 [X] 1-17,21-25 * page 786, paragraph 3 * | [Y] ABOU-GHARBIA M ET AL: "IV CONGRESS OF THE ECNP AGGRESSION AND ANXIETY ARE THE FIRST COMPONENTS TO RESPOND TO ANTIDEPRESSANT THERAPY", DRUG NEWS AND PERSPECTIVES, XX, XX, vol. 4, no. 10, 1 December 1991 (1991-12-01), pages 647 - 650, XP000568173, ISSN: 0214-0934 [Y] 1-17,21-25 * page 649, column 1, lines 1-10 * | [Y] VILLOSLADA PABLO ET AL: "Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 10, 15 May 2000 (2000-05-15), pages 1799 - 1806, XP001096055, ISSN: 0022-1007 [Y] 1-17,21-25 * abstract * DOI: http://dx.doi.org/10.1084/jem.191.10.1799 | [YA] BEVER C T: "THE CURRENT STATUS OF STUDIES OF AMINOPYRIDINES IN PATIENTS WITH MULTIPLE SCLEROSIS", ANNALS OF NEUROLOGY, BOSTON, US, vol. 36, 1994, pages S118 - S121, XP000653261, ISSN: 0364-5134 [Y] 1-17,21-25 * abstract * * page S120, column 1, paragraph 3 * [A] 18-20 DOI: http://dx.doi.org/10.1002/ana.410360728 | [YX] TANG LEI ET AL: "4-aminopyridine derivatives: A family of novel modulators of voltage-dependent sodium channels.", DRUG DEVELOPMENT RESEARCH, vol. 44, no. 1, May 1998 (1998-05-01), pages 8 - 13, XP001096100, ISSN: 0272-4391 [Y] 1-17,21-25 * page 10, column 2, paragraph 6 *[X] 18-20 DOI: http://dx.doi.org/10.1002/(SICI)1098-2299(199805)44:1<8::AID-DDR2>3.0.CO;2-L | [X] TANG L ET AL: "Effects of besipirdine at the voltage-dependent sodium channel.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 116, no. 5, 1995, pages 2468 - 2472, XP000603792, ISSN: 0007-1188 [X] 18-20 * abstract * | [X] EGLEN R M ET AL: "MUSCARINIC RECEPTOR LIGANDS AND THEIR THERAPEUTIC POTENTIAL", CURRENT OPINION IN CHEMICAL BIOLOGY, CURRENT BIOLOGY LTD, LONDON, GB, vol. 3, no. 4, August 1999 (1999-08-01), pages 426 - 432, XP000972296, ISSN: 1367-5931 [X] 26,27,32,33 * page 426, column 2, line 8; table 4 * * page 428, column 2, paragraph 2 * DOI: http://dx.doi.org/10.1016/S1367-5931(99)80063-5 |